This Pre-Solicitation opportunity from Department Of Health And Human Services was posted on May 28, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.
Renewal of licensing fee for the transgenic mouse strain, B-hIL2RA
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The contract involves the renewal of a licensing fee for the B-hIL2RA transgenic mouse strain, which is critical to the MIB's pre-clinical research on photoimmunotherapy, a treatment designed to selectively destroy regulatory T cells (Tregs) that suppress the immune response to cancer. These mice express the human form of IL2RA, allowing researchers to test antibodies and treatments intended for human use, thereby advancing the development of therapies aimed at improving anti-cancer immune responses. The solicitation, issued by the National Institutes of Health within the Department of Health and Human Services, facilitates continued access to this specialized mouse model essential for ongoing scientific exploration. The contract is a presolicitation with a response deadline in early June 2026, and the work is based in Maryland. It has no set-aside requirements and is classified under NAICS code 51321. The main contact for this contract is John Burton.
General Info
Agency
NAICS
Place of Performance
MD, 20892, USASet-Aside
Timeline
Submission Closed
Organization & Contact Information
Full Description
The MIB is conducting pre-clinical research on photoimmunotherapy (PIT), a targeted treatment approach that uses light activation to destroy specific cells. One area of this research focuses on IL2RA, a protein expressed on regulatory T cells (Tregs). These cells can reduce the immune system’s ability to respond effectively to cancer. The objective of this work is to selectively eliminate IL2RA-expressing Tregs in order to improve anti-cancer immune responses.
To support this research, MIB uses a transgenic mouse strain known as B-hIL2RA, which expresses the human form of IL2RA rather than the mouse form. Use of this model is essential because it enables evaluation of the same treatment materials, including antibodies, that are intended for future human application. As a result, this mouse strain has proven invaluable in the MIB’s ongoing research program.
The MIB is requesting to renew a licensing fee for transgenic mice, B-hIL2RA. B-hIL2RA transgenic mice.